New five-year data show a personalized mRNA vaccine, intismeran autogene, paired with the immunotherapy KEYTRUDA, cut the risk of melanoma coming back or causing death by nearly half compared with KEYTRUDA alone, offering a fresh, long-term result for patients after surgery.
Researchers reported findings from the phase 2b KEYNOTE-942 study at a major oncology meeting, tracking people with high-risk stage 3 and 4 melanoma after their tumors had been removed. The study followed 157 patients and split them into two groups: one receiving the combo of intismeran autogene plus pembrolizumab, and the other receiving pembrolizumab alone. After about five years, the combo showed a clear reduction in recurrence or death risk by 49 percent compared with pembrolizumab by itself.
Intismeran autogene is built from the mutations identified in each patient’s own tumor, aiming to teach the immune system to spot and attack those cancer cells. That personalized design feels like a targeted wake-up call to immune defenses rather than a one-size-fits-all shot. The appeal is obvious: tailor the vaccine to the tumor and let the body recognize what to hunt for.
Investigators described the benefits as “sustained and durable over time.” That wording matters because short-term effects are helpful, but lasting reductions in recurrence are the goal for patients who’ve already been through surgery. Durable improvements can change the conversation around follow-up care and long-term surveillance.
Safety was part of the picture and, according to the researchers, intismeran is “well-tolerated” with a “manageable” safety profile. The most commonly reported side effects were things like fatigue, injection-site pain, chills, fever and headache, which are familiar to anyone who’s had vaccines or immunotherapy. Importantly, the study reported no new long-term safety concerns and no severe vaccine-related adverse events tied to the personalized mRNA component.
This is phase 2b data, so while the signal is strong, regulators and clinicians will want confirmation in larger trials. That next step is already happening: the combination therapy is moving through a phase 3 study meant to validate and potentially broaden the results. If the late-stage data match these findings, the pathway to wider availability becomes much clearer.
Companies involved in the collaboration emphasized what the data suggest about mRNA’s role beyond infectious disease. Kyle Holen, MD, Moderna’s senior vice president and head of development, oncology and therapeutics, said this data highlights the “potential of a prolonged benefit … in patients with resected high-risk melanoma.” That kind of language signals confidence that the platform can deliver meaningful outcomes over years, not just months.
Merck also framed the result as a notable advance for patients facing a tough reality. Dr. Marjorie Green, senior vice president and head of oncology, global clinical development at Merck Research Laboratories, pointed out that many people with stage 3 or 4 melanoma face a real “significant risk of recurrence following surgery.” Reducing that risk is exactly the kind of clinical win oncologists and patients have been pushing for.
The companies noted encouraging five-year follow-up and flagged upcoming INTerpath trial results that will test the approach in several hard-to-treat cancers. Expanding beyond melanoma will be key to proving whether personalized mRNA oncology can become a platform for multiple tumor types. Success in other indications would change how drug developers think about tailoring immune approaches to individual tumors.
Patients and clinicians will watch the phase 3 outcome closely, since real-world impact depends on broader confirmation of both benefit and safety. For now, the data give a cautious dose of optimism: a personalized mRNA vaccine added to an established immunotherapy cut the long-term risk of recurrence nearly in half. That’s the kind of result that shifts attention from short-term responses to long-term survival strategies in cancer care.
